Table 3.
PI3K inhibitors in clinical trial in ALL.
Therapeutic Drug | Target (s) | Clinical Trial Status | Developer | Clinical Trial Number |
---|---|---|---|---|
Buparlisib (BKM120) | Pan-PI3K inhibitor | Phase I | Novartis | NCT01396499 |
Dactolisib (BEZ235) | PI3K/mTOR inhibitor | Phase I | Novartis | NCT01756118 |